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Diabetes mellitus (DM) complications were attributed to deposition of glycosylation
products on the interstitial tissue proteins and blood vessel walls, forming irreversible
advanced glycosylation end products (AGEs) (1). In diabetic retinopathy, deposition of
AGEs and plasma proteins in basement membranes resulted in retinal capillary closure,
retinal hemorrhages and micro-aneurysms (2). AGEs altered the expression of certain
genes that affect cellular growth, differentiation, inflammation and angiogenesis, which
are the basis of ischemic and proliferative diabetic retinopathy (3). Moreover, hypergly-
cemia stimulated inducible nitric oxide synthetase enzyme (iNOs) and nitric oxide (NO)
synthesis (4, 5). NO and iNOS modulated the proinflammatory and profibrotic pathways
in the progression of diabetic nephropathy (6). Additionally, endogenous antioxidant en-
zymes such as serum catalase, glutathione peroxidase (GPx) and increased glutathione
reductase (GR) were reported to decrease in chronic hyperglycemia (7). A synergistic re-
lation between AGEs and serum antioxidant enzymes was suggested (8).
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This study sought to determine the potential prophylac-
tic and antioxidant effects of aminoguanidine in experi-
mentally induced diabetes. Four groups of Wistar rats,
each composed of ten rats, were used. Two groups ser-
ved as control. In group 3, diabetes was induced by a sin-
gle intraperitoneal injection of streptozotocin (65 mg kg–1).
In group 4, diabetes was induced and treated with amino-
guanidine (100 mg kg–1 daily) orally for 3 months. Levels
of serum glucose, glutathione peroxidase, glutathione re-
ductase and erythrocytes catalase were analyzed on day
90 of the experiment. Retinal and kidney specimens were
examined histopathologically after sacrifice of the ani-
mals. A significant antioxidant effect of aminoguanidine
and its prophylactic role in diabetic retinopathy and ne-
phropathy were observed in experimental animals.
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Aminoguanidine is a breaker of AGEs (9) and a selective blocker of iNOS with an
antioxidant effect. It can decrease the oxidative modification in leucocytes and plasma
proteins in diabetic rats (10). Aminoguanidine ameliorated diabetic retinopathy after its
oral administration in a diabetic rat model (3). Furthermore, it improved diabetic nephro-
pathy in a diabetic rat model with preserved mesengial spaces, with no focal basement
membrane thickening and low urinary albumin excretion (11).
In this article, the effect of aminoguanidine in preventing or ameliorating retinal and
renal changes was investigated in experimentally induced diabetic rats as well as its re-
lation to antioxidant activity.
EXPERIMENTAL
To induce an animal model of diabetes, Wistar strain rats were injected intraperi-
toneally with a dose of 65 mg kg–1 streptozotocin (Sigma, Germany). About 25 % of the
rats died during the following 72 hours. The blood glucose level of the living rats was
measured after 48 hours, then weekly. Diabetes was defined as a fasting blood glucose
level exceeding 120 mg per 100 mL.
Animals
Forty Wistar rats weighing 140–150 grams, aged 3 months, of both sexes were used.
They were used in accordance with the institutional guidelines for use of animals in
ophthalmic and vision research. Approval of the institutional authority for laboratory
animal care and approval from the ethical committee were obtained. They were individu-
ally housed in separate cages under standardized temperature (25–28 °C), humidity
(50–60 %), and light (12 hours light-dark) conditions. They were fed the standard diet
and tap water for three months. Animals were divided into four groups of ten rats each.
Group 1 animals received a uniform volume of distilled water (0.5 mL) once daily by
means of a stomach tube (negative control). Group 2 animals received daily a single oral
dose of aminoguanidine (100 mg kg–1) dissolved in an appropriate volume of distilled
water through a stomach tube (positive control), beginning on day 3 of the experiment.
Group 3 diabetes model was induced and the animals were left untreated. Group 4 dia-
betes model was induced and the animals received a single oral dose of aminoguanidine
(100 mg kg–1) daily dissolved in an appropriate volume of distilled water through the
stomach tube on day 3 upon induction of diabetes.
Biochemical analysis
Blood samples were taken on day 90 of the experiment. Levels of plasma glucose
and creatinine were determined using commercial kits from Biocon (Germany). Gluta-
thione peroxidase activity (GPx), glutathione reductase activity (GR) and catalase enzyme
activity were determined by the colorimetric method described by kits from Diaclone
France.
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Histopathological examination
The animals were killed after 90 days by intravenous injection of toxic dose of a
phenobarbital (Sigma, Germany). Eyes were enucleated and dissected. Retinas were im-
mediately double fixed in 4 % glutraldehyde buffer, followed by 1.3 % osmium tetra-
oxide in phosphate buffer (pH 7.3), processed and embedded in araldite Cy 212. Semi-
-thin sections were stained with toluidine blue and examined by light microscopy (LM).
Renal tissues were dissected, fixed in 10 % formalin solution for 14–18 hours, pro-
cessed in a series of graded ethanol and embedded in paraffin. Paraffin sections of 5-mm
thickness were obtained and stained with hematoxylin and eosin for light microscopic
examination. The sections were examined and photographed with an Olympus light mi-
croscope (Olympus BX51, Olympus Optical Co., Japan) with an attached photograph ma-
chine (Olympus C-5050).
Statistical analysis
All results were expressed as mean ± SD. Comparison between groups was perfor-
med using ANOVA followed by a post hoc test and paired Student’s t-test.
RESULTS AND DISCUSSION
Biochemical analysis results are shown in Table I. The mean glucose and creatinine
serum levels, activity of catalase, glutathione peroxidase and glutathione reductase in
healthy control rats (groups 1 and 2) are displayed in Table I. Induction of diabetes for
three months in group 3 rats produced a noticeable deterioration regarding these para-
meters: the glucose level was increased by 240 %, catalase and glutathione reductase level
were decreased by 44 %, glutathione peroxidase was increased by 250 %, while creatinine
was increased by 130 % vs. control group 1.
Treatment of diabetic model rats with aminoguanidine (group 4) markedly inhib-
ited the above mentioned deterioration in catalase, glutathione peroxidase, and gluta-
thione reductase reaching values that were not significant by different compared to both
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1 79.75 ± 6.71a 91.30 ± 15.00 57.10 ± 10.91 4.19 ± 0.70 0.66 ± 0.01d
2 87.23 ± 14.99a 96.90 ± 11.86 55.70 ± 9.81 3.70 ± 0.73 0.60 ± 0.02b
3 193.65 ± 13.80a 51.40 ± 13.43c 145.50 ± 44.56c 2.33 ± 0.62c 0.85 ± 0.01c
4 141.41 ± 24.54a 90.30 ± 12.17c 67.90 ± 8.77c 3.65 ± 0.69c 0.68 ± 0.02b,c,d
Data are expressed as mean ± SD, n = 10.
Significant difference: a–c group 4 vs. groups 1, 2 and 3, resp. (p < 0.001), d group 4 vs. group 1 (p < 0.02).
control groups (1 and 2). These parameters were significantly improved compared to the
untreated diabetic model values (group 3) (p < 0.001).
It was observed that the serum glucose and creatinine also improved to 177 and 103 %
vs. the control group 1 values, respectively. However, they were still significantly higher
than control groups 1 and 2 (p < 0.001, p = 0.02), but were also significantly lower com-
pared to the diabetic model rats (group 3) (p < 0.001).
Histopathological examination of the retinas of control groups 1 and 2 showed nor-
mal pigment epithelium, outer and inner segments of the photoreceptors with normal
finger shaped rods and dark triangle shaped cones. The outer nuclear layer showed
normal nuclei and cytoplasm. The inner nuclear layer, outer and inner plexiform layers
were normal with no vascularization. The ganglion cell layer appeared normal with oc-
casional blood vessels (normal in rat retina) (Fig. 1a). The diabetic model (group 3) reti-
nas showed the stages of diabetic retinopathy with vacuolation of the pigment epithe-
lium, disruption and fragmentation of the photoreceptors (outer and inner segments); new
blood vessels were noticed in the inner nuclear layer of the retinas (Fig. 1b). Aminoguani-
dine treated diabetic model (group 4) retinas showed marked improvement with mini-
mal or no vacuolation of the pigment epithelium, slightly affected photoreceptors, especially
their inner segments and neovessels were not detected (Fig. 1c).
Current histological results showed a marked improvement in the retinal tissues of
the aminoguanidine treated model group (group 4). The pathological effects of AGEs in
diabetic retinopathy are a consequences of AGE-induced alteration in the expression of a
family of genes called the CCN family. These genes are responsible for retinal inflamma-
tion and angiogenesis, which are the basis of ischemic and proliferative diabetic retino-
pathy (3). These facts support and explain the beneficial effect of aminoguanidine as an
AGEs breaker that preserved the integrity of these genes and abrogated the induction of
retinopathy. The current results agree with those of Zheng et al. (13), who proved that amino-
guanidine inhibited degeneration of the neuronal and vascular cells of the retina.
Renal specimens in the control groups showed normal glomeruli with the tuft of
capillaries surrounded by Bowman’s capsule and normal space separating the visceral
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a) b) c)
Fig. 1. Light micrograph (toluidine blue): a) normal rat retina, b) distortion and fragmentation of
photoreceptors (small arrows) and newly formed blood vessels (big arrows), c) less vacuolation of
pigment epithelium (arrows) (magnification 500x).
and parietal layers. Renal tubules were lined with acidophilic cuboidal epithelium and
their lumens were patent (Fig. 2a). Diabetic model kidneys showed diabetic nephropa-
thy with loss of renal architecture, thick and fused capillary walls of the renal corpus-
cles. Bowman’s spaces were completely lost in some areas with thickening and adhesion
between visceral and parietal layers. Epithelial linings of the tubules were swollen and
vacuoles were noticed in their cytoplasm, with loss of the characteristic acidophilic stain.
The lumens were totally obliterated (Fig. 2b). Renal tissues in group 4 (the treated mo-
del) showed capillary corpuscles swelling with reduced and maintained Bowman’s spa-
ces. Tubular epithelia swelled with the narrowing of their lumens (Fig. 2c).
In the present work, a significant impairment of the serum antioxidant enzymes was
observed in the diabetic model rats (group 3). Glycation by AGEs and oxidation by stimu-
lated nitric oxide and peroxynitrites production (induced by chronic hyperglycemia) may
be responsible for the partial inactivation of these enzymes (9, 10). On treating the dia-
betic model rats with oral aminoguanidine (group 4), such impairment was abrogated
markedly. This beneficial effect may be attributed to its powerful ability to break AGEs at-
tached to the enzymes and to selective inhibition of the inducible nitric oxide synthase
enzyme (stimulated by hyperglycemia) (8). Improvement in the serum antioxidant en-
zymes was previously confirmed by many authors (10, 12).
A significant increase in the serum creatinine level in diabetic model animals (group
3) was observed. It coincided with the observed disturbed renal histological picture. To
explain the pathogenesis of diabetic nephropathy, evidence has been accumulated impli-
cating the formation of AGEs as a major factor in its pathogenesis (11). The intracellular
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a) b)
c)
Fig. 2. Light micrograph (hematoxylin and eosin):
a) normal kidney tissues: normal renal corpus-
cle (C), Bowman’s space (*) and renal tubules
(arrows); b) thickened capillary wall (*), absence
of Bowman’s space in some areas (small arrows)
and obliterated renal tubules (big arrows), c) re-
duced Bowman’s space (*) and slight swelling
of tubular epithelium (arrows) (magnification
500x).
basic fibroblast growth factor produced by the renal endothelial cells was subjected to
AGE modification following chronic hyperglycemia. Thereby a change of growth factor
properties and reduction of the mitogenic cellular activities was observed (7). In addi-
tion, the high concentrations of nitric oxide (induced by hyperglycemia) act as a positive
modulator of the proinflammatory and profibrotic pathways in the progression of renal
disease (6). In the current study, aminoguanidine administration (group 4) was found to
suppress markedly the renal histological changes in spite of chronic hyperglycemia. The
kidney function was improved, as indicated by the improved creatinine level. This is ex-
plained by the aminoguanidine ability to ameliorate the overexpression of profibrotic cy-
tokines. Also, it attenuated the type IV collagen deposition induced by AGEs contribut-
ing to the tubulointerstitial and glomerular lesions in diabetic mice (14–16). Moreover it
ameliorated the renal morpho-functional changes caused by the overproduction of NO
due to its ability to inhibit the inducible nitric oxide synthase enzyme (6).
CONCLUSIONS
Aminoguanidine, a glycated end product breaker and a selective inhibitor of induci-
ble nitric oxide synthetase enzyme, was found to play a significant role in ameliorating
retinal and renal pathologic changes induced by elevated blood glucose levels in dia-
betic rats. The alteration in catalase, glutathione reductase and peroxidase enzymes in-
duced by the high glucose level was prevented by oral aminoguanidine, indicating its
significant antioxidant effect. Further studies are recommended to elucidate its role in
diabetes mellitus and to investigate its interactions with antidiabetic drugs.
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S A @ E T A K
Potencijalna profilakti~ka uloga aminogvanidina u dijabeti~koj retinopatiji i
nefropatiji u eksperimentalnih `ivotinja
AMANY HASSAN M. EL SHAZLY, ATEF MOHAMED MAHMOUD i NEVINE SALAH DARWISH
U ovom radu ispitivano je potencijalno profilakti~ko i antioksidativno djelovanje
aminogvanidina u eksperimentalno induciranom dijabetesu. Ispitivanja su provedena na
~etiri skupine od 10 {takora. Dvije skupine bile su kontrolne skupine, u tre}oj skupini
dijabetes je induciran jednokratnom intraperitonealnom injekcijom streptozotocina
65 mg kg–1, a u ~etvrtoj dijabetes je induciran i tretiran aminogvanidinom 100 mg kg–1
dnevno, peroralno, tijekom 3 mjeseca. Devedesetog dana eksperimenta analizirane su kon-
centracije glukoze, glutation peroksidaze, glutation reduktaze i eritrocitne katalaze u se-
rumu. @ivotinje su `rtvovane, a uzorci retine i bubrega ispitivani su histopatolo{ki. Uo~en
je zna~ajan antioksidativni u~inak aminogvanidina i njegova profilakti~ka uloga u dija-
beti~koj retinopatiji i nefropatiji.
Klju~ne rije~i: aminogvanidin, diabeti~ka retinopatija, nefropatija, du{ikov oksid, glikozilirani krajnji
produkt, antioksidansi
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